American Skullcap

Metadata

Approved Indications

Commission E (Germany)

• No Commission E monograph exists for American Skullcap
• Scutellaria lateriflora is not part of the German or broader European phytotherapy tradition

ESCOP

• No ESCOP monograph has been published for American Skullcap

EMA/HMPC (European Medicines Agency)

• No EMA/HMPC monograph exists for American Skullcap
• The herb does not have a tradition of medicinal use in the EU sufficient to qualify for a traditional use registration

British Herbal Pharmacopoeia (BHP)

• American Skullcap is listed in the British Herbal Pharmacopoeia
• Traditional indications: nervous excitability, insomnia, anxiety, neuralgia, and as a sedative nervine

Agreement/Disagreement Between Bodies

• No European regulatory body has issued a therapeutic monograph
• The British Herbal Pharmacopoeia provides the most formal Western recognition of American Skullcap’s traditional use
• There is a disconnect between the herb’s widespread use by Western herbalists (particularly in North America and the UK) and its absence from European pharmacopoeial monographs
• The confusion with Baikal Skullcap in the literature and marketplace complicates assessment

Conditions Treated

Primary (Traditional Use, Preliminary Clinical Evidence)

• Anxiety and nervous tension: Core traditional indication; supported by two small RCTs showing anxiolytic and mood-enhancing effects
• Insomnia and sleep difficulties: Traditional nervine use; often combined with valerian or passionflower. No clinical studies specific to this indication

Secondary (Traditional Use, No Clinical Data)

• Nervous exhaustion / Neurasthenia: Traditional use for “nervous debility” and over-stimulation
• Muscle tension and spasm associated with nervous states: Traditional use as a spasmolytic nervine
• Withdrawal support: Traditional use to ease symptoms during withdrawal from benzodiazepines and other sedatives (practitioner-supervised only)

Traditional/Historical (Limited Evidence)

• Epilepsy and seizure disorders (historical use as “madweed” — not supported by modern evidence; not recommended)
• Rabies (historical folk use as “mad dog skullcap” — no evidence of efficacy)
• Headache associated with nervous tension
• Premenstrual tension and nervous irritability
• Neuralgia and neurological pain conditions

Mechanism of Action

Primary Mechanisms

GABAergic / Anxiolytic:

• Flavonoids in American Skullcap, particularly baicalin, baicalein, and scutellarein, bind to GABA-A receptors and modulate GABAergic neurotransmission
• The anxiolytic mechanism is believed to be similar to, but milder than, benzodiazepines — positive allosteric modulation of GABA-A receptors at the benzodiazepine binding site
• Unlike benzodiazepines, the effect appears to be subtler and is associated with mood improvement without significant sedation or cognitive impairment at standard doses

Neuroprotective / Antioxidant:

• Baicalein and scutellarein are potent antioxidants that cross the blood-brain barrier
• Inhibition of neuronal lipid peroxidation may contribute to the calming and neuroprotective effects
• Scutellarein has demonstrated anti-inflammatory effects in neuronal cell cultures

Secondary Mechanisms

Distinction from Baikal Skullcap (Scutellaria baicalensis)

• American Skullcap (S. lateriflora) and Baikal Skullcap (S. baicalensis) are different species with overlapping but distinct phytochemical profiles
• S. baicalensis root contains much higher concentrations of baicalin, baicalein, and wogonin; it is used primarily as an anti-inflammatory herb in TCM
• S. lateriflora aerial parts contain scutellarein and scutellarin as distinguishing compounds; it is used primarily as a nervine
• The two herbs should not be used interchangeably despite sharing a common name

Clinical Evidence Summary

Volume of Evidence

• Very limited. Only two small randomized controlled trials have been published. Traditional use documentation is more extensive but represents a lower level of evidence.

Key Studies

Anxiety / Mood

Detailed Notes on Key Studies

Wolfson & Hoffmann 2003:

• First published clinical trial on American Skullcap
• Acute dosing study (single-dose crossover design)
• Three herb conditions (100 mg x 1, 100 mg x 2, 350 mg x 1) all reduced anxiety vs. placebo
• 200 mg (two capsules of 100 mg) was the most effective dose
• No adverse effects on cognition, energy, or laboratory values (CBC, blood chemistry, liver function)
• Freeze-dried organic herb was used (not an extract)

Brock et al. 2014:

• Larger, longer-duration study (2-week treatment periods with crossover)
• 350 mg three times daily (1050 mg/day total)
• Significant improvement in global mood (Profile of Mood States) but not in anxiety specifically (Beck Anxiety Inventory)
• The authors noted that the non-anxious baseline of participants may have limited the ability to detect anxiolytic effects
• Suggests skullcap may enhance overall mood rather than acting specifically on anxiety

Evidence Gaps

• No studies in clinically anxious populations (both existing trials used healthy volunteers)
• No dose-response study across a range of doses
• No comparison with established anxiolytic herbs (valerian, kava, passionflower) or pharmaceuticals
• No studies on sleep quality or insomnia outcomes
• No long-term safety or efficacy data
• Mechanism of action in humans not confirmed (no pharmacokinetic studies)
• No studies using standardized extracts (both trials used whole herb preparations)

European vs US/Anglophone Consensus

Safety Profile

Contraindications

• Known hypersensitivity to American Skullcap or other Lamiaceae plants
• Concurrent use with sedative medications should be approached cautiously (additive sedation possible)

Drug Interactions

• No clinically documented drug interactions
• Theoretical additive effect with CNS depressants (benzodiazepines, barbiturates, alcohol) due to GABAergic mechanism — exercise caution
• Theoretical interaction with anticonvulsant medications (pharmacological basis is speculative)
• No known CYP enzyme interactions have been studied for S. lateriflora specifically

Side Effects

• Generally very well tolerated at standard doses
• Both published RCTs reported no significant adverse effects
• Mild drowsiness at higher doses (uncommon at standard doses)
• Gastrointestinal discomfort (rare)
• No evidence of hepatotoxicity from properly authenticated S. lateriflora (see Adulteration note below)

Hepatotoxicity / Adulteration Issue

• Historical case reports of skullcap-associated hepatotoxicity have been traced to products adulterated with or substituted by germander (Teucrium chamaedrys or Teucrium canadense), which contains hepatotoxic diterpenoids
• Properly authenticated Scutellaria lateriflora has not been associated with liver injury in clinical trials or in pharmacovigilance databases when the plant identity was confirmed
• Consumers should purchase from reputable sources that verify botanical identity through microscopic or phytochemical authentication

Pregnancy/Lactation

• Not recommended in pregnancy: Insufficient safety data; traditional caution applies
• Lactation: Insufficient data; not recommended during breastfeeding
• Not recommended for children under 12 years due to lack of safety data

Clinical Dosage

Standard Dosage Forms

British Herbal Pharmacopoeia Doses

• Dried herb: 1-2 g, three times daily
• Liquid extract (1:1 in 25% ethanol): 2-4 mL, three times daily
• Tincture (1:5 in 45% ethanol): 1-2 mL, three times daily

Clinical Trial Doses

• Wolfson & Hoffmann 2003: 100-350 mg freeze-dried herb (single acute doses)
• Brock et al. 2014: 350 mg freeze-dried herb, three times daily (1050 mg/day) for 2 weeks

Sources

• Wolfson P, Hoffmann DL. An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers. Altern Ther Health Med. 2003;9(2):74-78
• Brock C, et al. American skullcap (Scutellaria lateriflora): a randomised, double-blind placebo-controlled crossover study of its effects on mood in healthy volunteers. Phytother Res. 2014;28(5):692-698
• Awad R, et al. Bioassay-guided fractionation of lemon balm (Melissa officinalis L.) using an in vitro measure of GABA transaminase activity. Phytother Res. 2009;23(8):1075-1081
• Upton R, ed. Skullcap Scutellaria lateriflora L. American Herbal Pharmacopoeia and Therapeutic Compendium. 2009
• British Herbal Pharmacopoeia. British Herbal Medicine Association. 1983
• Brock C, et al. The use of Scutellaria lateriflora: a pilot survey amongst herbal medicine practitioners. J Herb Med. 2013;3(2):34-43
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD. Skullcap entry (updated 2020)
• Gafner S, et al. Alkaloids and phenylpropanoids from Scutellaria lateriflora. J Nat Prod. 2003;66(4):535-537

Connections

• Compare with Baikal Skullcap as a related Scutellaria species with a very different traditional use profile (TCM anti-inflammatory herb vs. Western nervine); the two should not be confused or used interchangeably
• Compare with Passionflower as a fellow anxiolytic herb with a stronger clinical evidence base, including a positive EMA traditional use monograph
• Related to Valerian as a classic nervine/sedative herb; valerian has much stronger clinical evidence and regulatory support (Commission E, ESCOP, EMA)
• Compare with Lemon Balm as a Lamiaceae family member with anxiolytic properties and rosmarinic acid content; lemon balm has Commission E approval
• Compare with Kava as an anxiolytic herb with substantially stronger clinical evidence (multiple RCTs, meta-analyses) but more complex safety considerations (hepatotoxicity debate)